Select a medication above to begin.
Icotyde
icotrokinra
Adult Dosing .
Dosage forms: TAB: 200 mg
psoriasis, moderate-severe plaque
- [200 mg PO qd]
- Info: give on empty stomach >30min before meal; do not cut/crush/chew tab, but may disperse tab in water
renal dosing
- [see below]
- eGFR >60: no adjustment; eGFR <60: not defined, caution advised
- HD/PD: not defined, caution advised
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: TAB: 200 mg
psoriasis, moderate-severe plaque
- [12 yo and older, >40 kg]
- Dose: 200 mg PO qd; Info: give on empty stomach >30min before meal; do not cut/crush/chew tab, but may disperse tab in water
renal dosing
- [see below]
- eGFR >60: no adjustment; eGFR <60: not defined, caution advised
- HD/PD: not defined, caution advised
hepatic dosing
- [not defined]
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- infection, active
- TB infection, active
- caution: TB infection, latent
- caution: TB infection risk
- caution: infection, chronic
- caution: infection, recurrent
- caution: infection risk
- caution: eGFR <60
Drug Interactions .
Overview
icotrokinra
IL-23 antagonist
- immunomodulatory effects
Contraindicated
Avoid/Use Alternative
Monitor/Modify Tx
Caution Advised
Safety/Monitoring .
Monitoring Parameters
no routine tests recommended
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; inadequate human data available; no known risk of embryo-fetal toxicity based on animal data at 27x and 297x MRHD, though risk of fetal loss and rib fusion based on animal data at 157x MRHD
Pregnancy Reporting
report any suspected fetal exposure to Janssen at 1-800-526-7736 or www.icotyde.com
Lactation
Clinical Summary
weigh risk/benefit while breastfeeding; no human data available to assess risk of infant harm or effects on milk production
Pharmacology .
Metabolism: for icotrokinra: catabolism; CYP450: unknown
Excretion: for icotrokinra: feces 37-81% (100% unchanged), urine 0.001% (100% unchanged); Half-life: 12h
Subclass: Interleukin-23 (IL-23) Antagonists ; Psoriasis, Systemic Agents
Mechanism of Action
for icotrokinra: selectively binds to IL-23 receptor and inhibits IL-23 cytokine-induced release of pro-inflammatory cytokines
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.